 PRINCETON, N.J., April 28, 2021 GLOBE NEWSWIRE -- Advaxis, Inc. Nasdaq: ADXS, a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination with pembrolizumab at the American Society of Clinical Oncology ASCO Annual Meeting being held virtually, on June 4-8, 2021. 